The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?

Doggrell, SA

Doggrell, SA (通讯作者),Griffith Univ, Sch Pharm & Med Sci, Brisbane, Qld, Australia.

EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (11): 1339

Abstract

Introduction The involvement of B-cells in multiple sclerosis has only recently emerged. Ublituximab is a monoclonal antibody that binds to the B-cell......

Full Text Link